Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.

A narrative review focused on how GLP-1 receptor agonists such as semaglutide are being studied in people with HIV, a population with high cardiometabolic burden. Reported benefits include reductions in weight, glycemia, and visceral and hepatic fat, though the authors caution that HIV-specific and older-population data are sparse and often used lower doses. Concerns around lean-mass loss and bone health are described as limited but generally reassuring. Useful as a signal of an emerging use-context, with the caveat that it is opinion-review rather than trial evidence.